|
|
Article: MedImmune In-Licenses Novel Inflammatory Disease Target and The Year in Review, Celgene Corp.
- Article from:
- M2 Presswire
- Article date:
- December 29, 2006
CopyrightCOPYRIGHT 2006 Normans Media Ltd. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
M2 PRESSWIRE-29 December 2006-U.S. Equity News: MedImmune In-Licenses Novel Inflammatory Disease Target and The Year in Review, Celgene Corp.(C)1994-2006 M2 COMMUNICATIONS LTD
RDATE:29122006
City of Industry, CA - Biotechnology industry alert provided by U.S. Equity News. MedImmune, Inc. (Nasdaq: MEDI) recently announced that it intends to develop a monoclonal antibody (MAb) targeting pathways within the CD28 receptor family for treatment of certain inflammatory diseases under a recently signed license agreement with Japan Tobacco, Inc. (JT). MedImmune strives to provide better medicines to patients, new medical options for physicians, rewarding careers ...